Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
NRG Oncology
Dana-Farber Cancer Institute
Institut du Cancer de Montpellier - Val d'Aurelle
Day One Biopharmaceuticals, Inc.
Bristol-Myers Squibb
G1 Therapeutics, Inc.
University of Chicago
Elevation Oncology
SWOG Cancer Research Network
Istari Oncology, Inc.
AstraZeneca
Merck Sharp & Dohme LLC
Altor BioScience
ADC Therapeutics S.A.
UroGen Pharma Ltd.
Sumitomo Pharma America, Inc.
Cedars-Sinai Medical Center
Pfizer
Pfizer
The University of Texas Health Science Center at San Antonio
University of Texas Southwestern Medical Center
SCRI Development Innovations, LLC
Hoosier Cancer Research Network
pharmaand GmbH
M.D. Anderson Cancer Center
Genmab
pharmaand GmbH
Bristol-Myers Squibb
Wake Forest University Health Sciences
H. Lee Moffitt Cancer Center and Research Institute
Hoosier Cancer Research Network
Eisai Inc.
Hoffmann-La Roche
Spectrum Pharmaceuticals, Inc
Spectrum Pharmaceuticals, Inc
Baylor College of Medicine
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Rainier Therapeutics
Rainier Therapeutics
Heat Biologics
University of California, San Francisco
The University of Texas Health Science Center at San Antonio
Fox Chase Cancer Center
National Institutes of Health Clinical Center (CC)
University of Colorado, Denver
Case Comprehensive Cancer Center
Icahn School of Medicine at Mount Sinai
The University of Texas Health Science Center, Houston